1. A Phase I Clinical Trial to Evaluate the Bioequivalence of an Adalimumab Biosimilar Adalimumab-WIBP and Humira ® .
- Author
-
Hu S, Liu Y, Yang L, Yang Y, Long F, Bao H, Zhang H, Yue X, Zhang J, Wang Z, Huang C, Wang J, Xia L, Pan Y, Zhang Y, and Gong F
- Abstract
Background and Objectives: The high costs associated with biological agents often limit accessibility for many patients, whereas biosimilars allow the wider application of biological treatment. The objectives of this phase I clinical trial were to compare the pharmacokinetics, immunogenicity, and safety profiles of the biosimilar adalimumab-WIBP and the reference product Humira
® and to assess the precision of the bioequivalence evaluation., Methods: In this randomized, double-blind, parallel-group bioequivalence study, 164 healthy male Chinese participants were selected and randomly divided into two groups on a 1:1 ratio. The subjects were administered a single 40 mg subcutaneous dose of either adalimumab-WIBP or Humira® . Blood samples extracted at multiple intervals after administration were analyzed to interpret pharmacokinetic parameters, and any adverse events were documented. Alongside ensuring safety measures, the subjects were monitored for immunogenicity., Results: The pharmacokinetic results demonstrated similar serum concentration-time curves in both groups. There were no significant differences in safety and no differences in immunogenicity profiles between the two groups. The bioequivalence was confirmed: the 90% confidence interval for the geometric mean ratio of the main pharmacokinetic parameters was within the range of 80-125%., Conclusion: The trial indicated the bioequivalence between adalimumab-WIBP and the reference product Humira® based on pharmacokinetics, immunogenicity, and safety profile. These findings reinforce the use of the adalimumab-WIBP biosimilar as a possible therapeutic alternative to Humira® ., Competing Interests: Declarations Conflict of interest Lu Yang, Xin Yue, Jiayou Zhang, Zejun Wang, and Yongbing Pan are employees of Wuhan Institute of Biological Products Co. Ltd., Wuhan, China. Funding This research was funded by the Wuhan Institute of Biological Products Co. Ltd., Wuhan, China. Human ethics approval declaration This study was conducted in line with the International Conference on Harmonization Standards for Good Clinical Practice, the Helsinki Declaration, and relevant national or international regulatory requirements. The study protocol was reviewed and approved by the hospital ethics committee (approval number: GCP-ICT-2019-28.01, approval date: May 13, 2019) and was registered at NMPA (CXSL1800014). Consent to participate Informed consent was obtained from all patients before undergoing any research procedures. Consent for publication Not applicable. Code availability Not applicable. Data availability Statement The datasets used in this study can be obtained from the corresponding author upon request. Author contributions All authors made a significant contribution to the work reported, whether that was in the conception, study design, execution, acquisition of data, analysis and interpretation or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)- Published
- 2024
- Full Text
- View/download PDF